首页> 外文期刊>European Archives of Oto-Rhino-Laryngology >Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma
【24h】

Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma

机译:金属蛋白酶ADAM12,驱动蛋白14和检查点抑制剂1作为喉癌的新分子标记

获取原文
获取原文并翻译 | 示例
           

摘要

The assessment of gene expression profile in laryngeal cancer allows implementation of molecular biology methods in diagnostics, as well as in prognosticating the course of disease, thus allowing taking most optimal decisions as regards the method of treatment, scope of surgical procedure, or the necessity of adding complementary radiotherapy. The aim of the project was to analyze the gene expression profile in laryngeal cancer using oligonucleotide microarrays, having in mind searching new molecular markers for that carcinoma. The study comprised a group of 43 patients (38 males and 5 females) suffering from squamous cell laryngeal carcinoma, diagnosed and surgically treated in the years 2005–2007 in the ENT Department of the Silesian Medical University in Katowice, Poland. RNA was isolated from frozen tissue fragments, with the use of columns RNeasy Midi and Mini Kit (Qiagen). For the examination of gene expression profile, oligonucleotide microarrays of high density were used, provided by Affymetrix (U 133 2.0 PLUS) containing over 54,000 probes for over 47,000 transcripts. Four genes previously not examined in that respect in laryngeal carcinoma, occurred to be good markers of the neoplasm. They are: metal-proteinase ADAM12, cyclin-dependent kinase 2–CDK2, kinesin 14–KIF14, suppressor 1 of checkpoint–CHES1. The analysis of gene expression profile allows, in laryngeal carcinoma, to point out to new genes, which in future may become molecular markers of the carcinoma.
机译:喉癌中基因表达谱的评估可以在诊断以及疾病的预后中采用分子生物学方法,从而可以在治疗方法,手术范围或是否必要方面做出最佳决定。增加辅助放疗。该项目的目的是使用寡核苷酸微阵列分析喉癌的基因表达谱,同时考虑寻找该癌的新分子标记。这项研究包括一组43例鳞状细胞喉癌患者(38例男性和5例女性),这些患者在2005-2007年间在波兰卡托维兹西里西亚医科大学的耳鼻喉科进行了诊断和手术治疗。使用RNeasy Midi和Mini Kit(Qiagen)柱从冷冻的组织片段中分离RNA。为了检查基因表达谱,使用了由Affymetrix(U 133 2.0 PLUS)提供的高密度寡核苷酸微阵列,其中包含超过54,000个探针,超过47,000个转录本。以前在喉癌中未进行过检查的四个基因,是肿瘤的良好标志物。它们是:金属蛋白酶ADAM12,细胞周期蛋白依赖性激酶2–CDK2,驱动蛋白14–KIF14,检查点–CHES1的抑制剂1。基因表达谱的分析允许在喉癌中指出新的基因,将来可能成为癌的分子标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号